Olivér Závoti

Mr. Olivér Závoti

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2025 in The Journal of Physiology
Verified
Journal Article
Open access
OZOlivér Závoti
Olivér Závoti
LCLászló Csanády
László Csanády
Cystic fibrosis (CF) is a life‐threatening condition caused by pathogenic mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel. While most patients with frequent mutations are treated with a combination of corrector and potentiator drugs (elexacaftor–tezacaftor–ivacaftor, ETI), for many rare variants no such treatment is approved. Here we characterized the molecular pathologies of five rare CF‐associated mutants (G126D, I336K, T465I, T582I and D984V), and evaluated their responsiveness to ETI treatment. Channel expression was investigated by western blot from HEK‐293T cells transiently expressing mutant channels, with or without corrector drugs (elexacaftor and tezacaftor). Drug efficiency was assessed by the enhancement of channel glycosylation. Maturation was mildly (T582I, G126D) to severely (T465I) defective for all five mutants, but could be restored to wild‐type levels by incubation with corrector drugs. Gating properties and responses to potentiator drugs (ivacaftor and elexacaftor) were assessed in macroscopic and single‐channel inside‐out patch‐clamp recordings from mutant channels expressed in Xenopus laevis oocytes. Mutations G126D, T582I, I336K and T465I markedly decreased channel open probability, with the greatest reduction being caused by mutation T465I. Mutations G126D, I336K and T465I also slightly impaired unitary conductance. Applying potentiator drugs boosted gating for all variants, producing multifold increases in macroscopic currents. In conclusion, all five mutations impair channel maturation and gating to various degrees, but a normal glycosylation pattern can be restored with correctors, and channel gating can be enhanced with potentiators. These in vitro observations suggest that ETI treatment would be beneficial for CF patients carrying an allele with any of the five mutations. image Key points: Mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel cause cystic fibrosis. Highly efficient modulator therapy has been approved for ∼90% of cystic fibrosis patients, but a large number of rare mutations are not yet eligible for treatment. Five rare CFTR mutations found in cystic fibrosis patients in Hungary and worldwide are shown here to produce complex channel pathologies that to differing degrees affect protein maturation, channel gating and anion permeation through the open pore. All five variants respond strongly to clinically employed modulator drugs that boost channel surface expression and gating. The results help us understand how these CFTR mutations lead to cystic fibrosis, and suggest that patients carrying any of the five variants would probably benefit from modulator therapy.

16 January 2023 in Membranes
Verified
Journal Article
Open access
PDF file
CVConstantinos Voniatis
Constantinos Voniatis
OZOlivér Závoti
Olivér Závoti
KMKenigen Manikion
Kenigen Manikion
BBBálint Budavári
Bálint Budavári
AHAngela Jedlovszky Hajdu
Angela Jedlovszky Hajdu
Poly(vinyl-alcohol) hydrogels have already been successfully utilised as drug carrier systems and tissue engineering scaffolds. However, lacking mechanical strength and suturability hinders any prospects for clinical and surgical applications. The objective of this work was to fabricate mechanically robust PVA membranes, which could also withstand surgical manipulation and suturing. Electrospun membranes and control hydrogels were produced with 61 kDa PVA. Using a high-speed rotating cylindrical collector, we achieved fibre alignment (fibre diameter: 300 ± 50 nm). Subsequently, we created multilayered samples with different orientations to achieve multidirectional reinforcement. Finally, utilising glutaraldehyde as a cross-linker, we created insoluble fibrous-hydrogel membranes. Mechanical studies were performed, confirming a fourfold increase in the specific loading capacities (from 0.21 to 0.84 Nm2/g) in the case of the monolayer samples. The multilayered membranes exhibited increased resistance from both horizontal and vertical directions, which varies according to the specific arrangement. Finally, the cross-linked fibrous hydrogel samples not only exhibited specific loading capacities significantly higher than their counterpart bulk hydrogels but successfully withstood suturing. Although cross-linking optimisation and animal experiments are required, these membranes have great prospects as alternatives to current surgical meshes, while the methodology could also be applied in other systems as well.